shutterstock_1435040315_rafapress

rafapress / Shutterstock.com

15 June 2021Big PharmaMuireann Bolger

Allergan’s Forest to face jury in antitrust suit over Alzheimer drug

Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda (memantine), from the marketplace.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

AbbVie’s pending Allergan takeover moves closer after drug divestments

28 January 2020 Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.

Actavis completes $71bn acquisition of Allergan

17 March 2015 Dublin-based pharmaceutical company Actavis has completed its acquisition of Allergan for $71 billion.

More on this story

AbbVie’s pending Allergan takeover moves closer after drug divestments

28 January 2020 Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.

Actavis completes $71bn acquisition of Allergan

17 March 2015 Dublin-based pharmaceutical company Actavis has completed its acquisition of Allergan for $71 billion.

More on this story

AbbVie’s pending Allergan takeover moves closer after drug divestments

28 January 2020 Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.

Actavis completes $71bn acquisition of Allergan

17 March 2015 Dublin-based pharmaceutical company Actavis has completed its acquisition of Allergan for $71 billion.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent